We are pleased to share that Pauli Wong, Principal at Eagle IP, was recently invited by the HKUST Entrepreneurship Center to lead a seminar titled "[ENTR101] Protecting Your Start-ups through IP."

Addressing a dynamic group of student entrepreneurs, faculty, and aspiring founders at the Hong Kong University of Science and Technology (HKUST), Pauli provided a foundational roadmap for navigating the complexities of intellectual property in the early stages of a business.

At Eagle IP, we take pride in supporting the next generation of innovators. By bridging the gap between technical research and legal protection, we help start-ups transform their academic breakthroughs into scalable, protected ventures. We would like to thank the HKUST Entrepreneurship Center for hosting this session and for their commitment to fostering a robust IP culture within the university ecosystem.

我們過去活動

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

2026年5月8日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Eagle IP to Attend INTA 2026 Annual Meeting in London

2026年5月2日

Eagle IP’s Jennifer Che to Attend LSPN North America Spring 2026 in Boston

2026年4月29日

Pauli Wong to Share IP Strategy Insights at HKLSS Entrepreneurship Series 2026

2026年4月25日

Eagle IP and HKSTP Host AIPLA Women in IP Global Networking Event

2026年4月16日

Recommended Insights

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
閱讀更多 >

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
閱讀更多 >

First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

2023年3月8日
What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]
閱讀更多 >

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

2023年1月4日
Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]
閱讀更多 >
Top crossarrow-right